Related Experiment Video
Updated: Jan 5, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Case 271: Metronidazole-induced Encephalopathy
Yankai Sun1, Philip J Overby1, Hasit Mehta1
1From the Section on Neuroradiology, Department of Radiology (Y.S., H.M.), and Section on Pediatric Neurology, Department of Pediatrics (P.J.O.), New York Medical College, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595.
Abstract:
HistoryAn 11-year-old boy taking oral antibiotics for Fusobacterium meningitis diagnosed 3 months earlier presented to the emergency department with a 1-week history of intermittent emesis, dizziness, and vertigo and a 1-day history of wobbly gait and bilateral lower extremity paresthesia without confusion. His metabolic profile was normal. Contrast material-enhanced MRI of the brain was performed.
Insights
An 11-year-old boy with Fusobacterium meningitis experienced new neurological symptoms. Brain MRI with contrast was performed to investigate the cause.
Area of Science:
- Neurology
- Infectious Diseases
- Radiology
Background:
- A pediatric patient presented with worsening neurological symptoms, including vertigo and gait disturbance.
- The patient had a history of Fusobacterium meningitis treated with oral antibiotics for 3 months.
- No confusion or metabolic abnormalities were noted.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

